Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cytovance Biologics | Contract Pharma

What are you searching for?

Sign in
Breaking News

Cytovance Biologics

Jeffrey Su, Ph.D., has been named vice president of bioanalytical development at Cytovance

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jeffrey Su, Ph.D., has been named vice president of bioanalytical development at Cytovance Biologics. Dr. Su will head up the bioanalytical development laboratory supporting existing and new client needs. This lab is part of the ongoing strategic expansion of the facilities to add scientific capabilities and the 1,000L Microbial, 1,000L and 5,000L Mammalian process train capacity. “I see this addition as a key placement to meet the needs of our expansion,” said Darren Head, president chief executive officer of Cytovance.

Dr. Su has more than 17 years experience in the pharmaceutical/biotech industry. He has extensive experience in R&D, Process development, cGMP manufacturing, analytical development and quality systems, as well as regulatory affairs. He has successfully managed projects involving partners in the U.S., Asia, Canada and Europe.

Before joining Cytovance, Dr. Su was the vice president of operation and product development at Femta Pharmaceuticals in San Diego, CA. Prior to his tenure at Femta, he served as the deputy director and platform leader for formulation at Sanofi Pasteur, the senior director for manufacturing and control at CancerVax Inc., and other roles at Dow Chemical, Tanox, Pharming Healthcare, Medarex, Human Genome Sciences and Roche.

The bioanalytical development lab will be housed in Cytovance’s multi-product cGMP production facility in Oklahoma City, OK. The 44,000-sq.-ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production, according to the company.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics